DNAM-1 plays a pivotal role in NK cell-mediated tumor immunosurveillance, as studies have demonstrated the expression of DNAM-1 ligands CD155 and CD112 across a wide spectrum of solid tumors and hematologic malignancies. This evidence concerns the gene CD226 and hematologic disorder.